pharmaceutical company
H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act
H.R.965/ S.340, CREATES Act
H.R.1503, Orange Book Transparency Act
H.R.1520, Purple Book Continuity Act
H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act
H.R.2376/ S.1227, Prescription Pricing for the People Act
S.1416, Affordable Prescriptions for Patients Act
S.1895, Lower Health Care Costs Act
H.R. 1499, Protecting Consumer Access to Generic Drugs Act
Administration review of drug pricing policies H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act
H.R.965/ S.340, CREATES Act
H.R.1503, Orange Book Transparency Act
H.R.1520, Purple Book Continuity Act
H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act
H.R.2376/ S.1227, Prescription Pricing for the People Act
S.1416, Affordable Prescriptions for Patients Act
S.1895, Lower Health Care Costs Act
H.R. 1499, Protecting Consumer Access to Generic Drugs Act
Administration review of drug pricing policies
HCR - Health Issues PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
POLSINELLI PC
1401 Eye Street, NW, Suite 800, Washington, DC, 20005, US
SYLVIA STANOJEV KORNEGAY JAMES DAVIDSON STEVEN STRANNE HARRY ANASTASIOS SPORIDIS JULIUS W HOBSON SYLVIA STANOJEV KORNEGAY JAMES DAVIDSON STEVEN STRANNE HARRY ANASTASIOS SPORIDIS JULIUS W HOBSON